Post Hoc Analysis of Nascent Geographic Atrophy Progression in the GATHER1 Trial Anat Loewenstein (Israel)
Brolucizumab for Treatment of Diabetic Macular Edema (DME): 100-Week Results from the KESTREL and KITE Studies Andrew Chang (Australia)
Personalised Treatment Interval (PTI) Dosing Dynamics in the Phase 3 YOSEMITE/RHINE Trials of Faricimab in Diabetic Macular Edema TBA
Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Results From the Phase 3 TENAYA and LUCERNE Trials De-Kuang Hwang (Tajikistan)
VOYAGER: An Innovative Real-world Study of the Port Delivery System With Ranibizumab and Faricimab in Patients With nAMD and DME Adrian Koh (Singapore)
